Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications in People With T1D (Precision T1D Platform)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 57
- 试验地点
- 2
- 主要终点
- Markers of Renal Health [Safety and Tolerability]
研究概览
简要总结
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health & Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
详细描述
This is a multicenter, open label pilot platform study to evaluate the impact of allocating patients with T1D and early signs of HF/DKD to targeted therapies based on their disease pathway activation signatures. The hypothesis is that stratifying T1D patients by molecularly-defined endophenotypes enables the use of targeted therapies that can more effectively prevent or slow cardio-renal complications.
There is no randomized allocation to treatment arms; rather, the eligible participant's clinical and biomarker data will be reviewed by the Molecular T1D Board which will adjudicate each participant to a treatment arm based on their based on their disease pathway activation signatures. Activation of different treatment arms may be initiated at different time points during the study.
The following sections describe the master protocol, outlining the requirements across all treatment arms, including the study-wide inclusion and exclusion criteria and study-wide procedures. Appendix A outlines any treatment arm/investigational agent specific information, including defining additional treatment-specific eligibility criteria and required study procedures.
The study schema can be found in Section 1.2 and the Schedule of Activities (SoA) in Section 1.3. Potential participants will undergo a two-part consent and screening process. The initial consent and screening visit will be limited to activities necessary for assessment by the Molecular T1D Board. Following review by the Molecular T1D Board, participants will be adjudicated to one treatment arm. At this time, participants will undergo the second consent and screening step, which will include information about specific requirements for their assigned investigational arm and, if in agreement, a complete eligibility assessment via a full screening visit. If the participant is deemed eligible, they will be notified and investigational product will be mailed to them directly. The screening visit results will also serve as the baseline results provided the first dose of study drug is taken within 14 (target) to 21 (limit) days of the screening visit. If more than 21 days, a retest of all laboratory measures will be performed.
Participants will receive open label treatment for 26 weeks, with planned study visits at weeks 2, 6, 12, 26, and 30. The total study duration of participation will be up to 36 weeks, inclusive of the screening period. Active study participation will conclude at Week 30 visit. Following completion of active study participation, participants will enter a passive follow-up period during which the study team may collect information on vital status, survival, hospitalizations, and other relevant clinical outcomes through review of medical records and other authorized data sources for up to 12 months after study participation ended. No additional protocol-required visits, procedures, or interventions will be conducted during the passive follow-up period. Participants will be enrolled in this study at Oregon Health & Science University and the University of Michigan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of T1D, defined as hyperglycemia requiring treatment with insulin within one year from diagnosis or, if the onset was after age 35 years, documentation of the presence of hyperglycemia and one or more of the following:
- •presence of circulating T1D-associated autoantibodies, or
- •history of hospitalization for diabetic ketoacidosis, or
- •documented plasma C-peptide below the limit of detection with standard assay (with concurrent blood glucose >100 mg/dL)
- •Aged 18-75 years, inclusive
- •T1D duration >10 years
- •HbA1c: 7-10%
- •Meets one of the following, either
- •UACR > 30 mg/dl with eGFR ≥ 60mL/min/1.73 m2 and receiving standard of care therapy for early DKD Stage 2, including renin angiotensin system blockade (RASB), unless contraindicated or not tolerated, or
- •Early (Stage B HF) defined as NT-proBNP ≥125 pg/mL
- •Willing and able to adhere to schedule of activities and protocol requirements, including written informed consent
排除标准
- •Diagnosis of Type 2 diabetes or monogenic forms of diabetes or diabetes secondary to pancreatic disease
- •Use of any active platform treatment arms outside study assignment within 2 months prior to screening. See Appendix A for active treatment arms
- •Current use of GLP-1 receptor agonists or other non-glucose lowering agent
- •Use of aldosterone inhibitors within 2 months prior to screening
- •Immunosuppressive medications within 3 months prior to screening
- •Systolic BP>160 or diastolic BP >95 mmHg at screening
- •History of ≥3 severe hypoglycemic events requiring third-party assistance for correction within 3 months prior to screening
- •Evidence of any episode of DKA or non-ketotic hyperosmolar state within 12 months prior to screening
- •Serum potassium > 5.0 mmol/L at screening
- •Absolute neutrophil count < 2.0 × 109 per L at screening
- •Platelet count < 120 × 109 per L at screening
- •Known active tuberculosis, hepatitis B or C at screening, or history of HIV
- •Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites or hepatic encephalopathy), and/or known diagnosis of cirrhosis based on liver biopsy, imaging, or elastography, and/or AST or ALT >2 times upper limit of normal, and/or total bilirubin >1.3 times upper limit of normal at screening
- •History of severe acquired immune deficiency syndrome or severely immunocompromised status in the opinion of the study site investigator
- •History of biopsy-proven non-diabetic CKD
- •History of any other cause of HF (viral, congenital, valvular)
- •History of heart or renal transplant or currently on chronic dialysis
- •Cancer treatment, excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer, within one year prior to screening
- •Illicit drug abuse within 6 months prior to screening in the opinion of the study site investigator
- •Current heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week)
- •Participation in another interventional clinical research study within 30 days prior to screening
- •Breastfeeding, pregnancy, or unwillingness to be on contraception during the trial
- •Presence of a clinically significant medical history, physical examination, laboratory finding or other identified study site investigator concern that may interfere with any aspect of study conduct or interpretation of results
研究组 & 干预措施
Finerenone
Study participants with biomarker profiles showing a match for finerenone will be adjudicated to this treatment arm. The clinically recommended dose for finerenone based on manufacturer guidelines is 20 mg once daily (oral) if screening eGFR is ≥60 mL/min/1.73 m2.
干预措施: Finerenone (Drug)
Sotagliflozin
Study participants with biomarker profiles that match with sotagliflozin will be adjudicated to this treatment arm. The clinically recommended dose of sotagliflozin is 200 mg per the manufacturer guidelines. The dose of 200 mg has a lower DKA risk and similar kidney benefits to the higher doses.
干预措施: Sotagliflozin (Drug)
结局指标
主要结局
Markers of Renal Health [Safety and Tolerability]
时间窗: 26 weeks
The primary efficacy endpoints are measures of early (week 26) outcomes on markers of renal health, defined as the percent change from baseline to week 26 in UACR.
Markes of Cardio Health [Safety and Tolerability]
时间窗: 26 weeks
The primary efficacy endpoints are measures of early (week 26) outcomes on markers of cardio health as defined by the percent change from baseline to week 26 in NT-proBNP.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: 26 weeks
The primary safety endpoints are defined as incidence of serious adverse events, adverse events and clinically significant abnormal laboratory tests.
次要结局
- Immediate Outcomes of Renal Health (week 6)(20 weeks)
- Immediate Outcomes of Cardio Health (week 6)(20 weeks)
- Immediate (week 6) and Early (week 26) Outcomes of Nephron Function Failure(26 weeks)
研究者
Rodica Busui
Trial Chair and Principal Investigator at OHSU
Oregon Health and Science University